Among the immune checkpoint inhibitors, PD-1/PD-L1 and CTLA-4 inhibitors showed promising therapeutic outcomes, and some have been approved for certain cancer treatments (e.g., melanoma), while others are under phase III and IV clinical trials [5]. Here, CTLA4 is linked to cancer.